87
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

A state-of-art review on collagenase Clostridium Histolyticum and Peyronie’s disease: drug profile, clinical evidence and safety outcomes

ORCID Icon, &
Pages 559-564 | Received 01 Feb 2020, Accepted 16 Mar 2020, Published online: 29 Apr 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Eric Chung & Faysal A. Yafi. (2022) Pharmacotherapy in Peyronie’s disease: a state-of-the-art review on established contemporary and emerging drugs. Expert Opinion on Pharmacotherapy 23:9, pages 1035-1042.
Read now

Articles from other publishers (4)

Georgi Tosev, Evgeniya Vladeva & Ivaylo Dimov. (2023) МODERN NON-INVASIVE METHODS FOR TREATING PEYRONIE'S DISEASE. World Science:1(79).
Crossref
Eric Chung, Du-Geon Moon, Jiang Hui, Hong-Chiang Chang, Lukman Hakim, Koichi Nagao, Ronny Tan, Siu King Mak, Kavirach Tantiwongse, Haocheng Lin, Dung Ba Tien Mai, Quang Nguyen, Hui Meng Tan, Yoshikazu Sato, Bang-Ping Jiann, Kwangsung Park, Zhong Cheng Xin & Hyun-Jun Park. (2023) Clinical recommendations on penile reconstructive and prosthetic surgery: a consensus statement from the Asia-Pacific Society of Sexual Medicine. Sexual Medicine 11:2.
Crossref
Eric Chung & Juan Wang. (2022) Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie’s Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates . Investigative and Clinical Urology 63:5, pages 563.
Crossref
Ria D. Corder, Sashi V. Gadi, Robert B. Vachieri, Friederike L. Jayes, John M. Cullen, Saad A. Khan & Darlene K. Taylor. (2021) Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion. Acta Biomaterialia 134, pages 443-452.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.